A single family office based in New York, NY. The group has significant experience in the healthcare space and has made several successful investments in a variety of life science companies. Initial investments can range widely depending on the needs and stage of development of the company, with allocations from $100K – $4M. Investments may come in the form of straight equity or convertible notes. The firm may lead or co-invest in a syndicate and typically looks to take a meaningful stake in portfolio companies. The group may seek a board seat depending on the size of the investment and their role in the financing round, however it is not a requirement.
The firm is fairly opportunistic in the healthcare space and is interested in therapeutics, medical devices and increasingly digital health/healthcare IT, however the group favors breakthrough technologies. As for therapeutics, The firm is most interested in companies with POC/Ph. II data, but will evaluate companies with some earlier clinical data as well. In the medical device space, the group will consider companies yet to obtain FDA approval, but looks for companies with a clear path to approval and commercialization. The firm has historically focused on biotech and medtech companies, but plans to become more active in the healthcare IT space going forward.
The firm has no strict management team requirements, but favors strong management teams with considerable experience. The group tends to focus on U.S.-based companies, but has no geographic restrictions.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment